Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin

Multi-Center, Open-Label Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin (Protocol 20020168)

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00111982

Enrollment

Registered

2005-05-30

Start date

2003-12-31

Completion date

2006-02-28

Last updated

2010-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

bilateral, idiopathic Parkinson's Disease

Brief summary

The purpose of this study is to determine long-term efficacy of continuous IPu liatermin infusion administered with concomitant standard anti-Parkinsonian therapy.

Interventions

BIOLOGICALLiatermin

Liatermin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

35 Years to 70 Years

Healthy volunteers

Inclusion criteria

- Completion of the 20020168 protocol

Design outcomes

Primary

Measure	Time frame
Percent change in UPDRS	24 months

Secondary

Measure	Time frame
Incidence of treatment emergent and device related adverse events	24 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026